Cargando…
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particula...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072681/ https://www.ncbi.nlm.nih.gov/pubmed/32012988 http://dx.doi.org/10.3390/cancers12020308 |
_version_ | 1783506463173378048 |
---|---|
author | Lamb, Lydia S. Sim, Hao-Wen McCormack, Ann I. |
author_facet | Lamb, Lydia S. Sim, Hao-Wen McCormack, Ann I. |
author_sort | Lamb, Lydia S. |
collection | PubMed |
description | Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling. |
format | Online Article Text |
id | pubmed-7072681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70726812020-03-19 Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” Lamb, Lydia S. Sim, Hao-Wen McCormack, Ann I. Cancers (Basel) Review Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling. MDPI 2020-01-28 /pmc/articles/PMC7072681/ /pubmed/32012988 http://dx.doi.org/10.3390/cancers12020308 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lamb, Lydia S. Sim, Hao-Wen McCormack, Ann I. Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title_full | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title_fullStr | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title_full_unstemmed | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title_short | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
title_sort | exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature—“are we there yet?” |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072681/ https://www.ncbi.nlm.nih.gov/pubmed/32012988 http://dx.doi.org/10.3390/cancers12020308 |
work_keys_str_mv | AT lamblydias exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet AT simhaowen exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet AT mccormackanni exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet |